Literature DB >> 15117842

Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury.

Zheqing Cai1, Gregg L Semenza.   

Abstract

BACKGROUND: Parenteral administration of recombinant human erythropoietin (rhEPO) to rats induces protection against myocardial ischemia/reperfusion injury 24 hours later. However, the mechanisms by which rhEPO mediates protection have not been determined. METHODS AND
RESULTS: rhEPO was perfused into isolated rat hearts over 15 minutes immediately before 30 minutes of no-flow ischemia and 45 minutes of reperfusion. Compared with saline-perfused control hearts, recovery of left ventricular developed pressure was increased in rhEPO-perfused hearts. rhEPO also increased AKT activity and decreased apoptosis. All of these effects were blocked when the phosphatidylinositol-3-kinase inhibitor wortmannin was infused with rhEPO.
CONCLUSIONS: rhEPO provides immediate protection against ischemia/reperfusion injury in the isolated perfused rat heart that is mediated by the phosphatidylinositol-3-kinase pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117842     DOI: 10.1161/01.CIR.0000127954.98131.23

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  58 in total

Review 1.  Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning.

Authors:  Gregg L Semenza
Journal:  Biochim Biophys Acta       Date:  2010-08-21

Review 2.  Mechanism of cardioprotection by early ischemic preconditioning.

Authors:  Xiulan Yang; Michael V Cohen; James M Downey
Journal:  Cardiovasc Drugs Ther       Date:  2010-06       Impact factor: 3.727

3.  Erythropoietin induces positive inotropic and lusitropic effects in murine and human myocardium.

Authors:  David Hefer; Ting Yi; Donald E Selby; David E Fishbaugher; Sarah M Tremble; Kelly J Begin; Prospero Gogo; Martin M Lewinter; Markus Meyer; Bradley M Palmer; Peter Vanburen
Journal:  J Mol Cell Cardiol       Date:  2011-10-14       Impact factor: 5.000

4.  Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.

Authors:  John Doukas; Wolfgang Wrasidlo; Glenn Noronha; Elena Dneprovskaia; Richard Fine; Sara Weis; John Hood; Anthony Demaria; Richard Soll; David Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-15       Impact factor: 11.205

5.  Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis.

Authors:  Ping Fu; Murat O Arcasoy
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

6.  Erythropoietin prevents endothelial dysfunction in GTP-cyclohydrolase I-deficient hph1 mice.

Authors:  Livius V dʼUscio; Anantha V R Santhanam; Zvonimir S Katusic
Journal:  J Cardiovasc Pharmacol       Date:  2014-12       Impact factor: 3.105

7.  Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure.

Authors:  Sharad Rastogi; Makoto Imai; Victor G Sharov; Sudhish Mishra; Hani N Sabbah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-24       Impact factor: 4.733

8.  JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells.

Authors:  A C Breggia; D M Wojchowski; J Himmelfarb
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24

Review 9.  The role of estrogen and receptor agonists in maintaining organ function after trauma-hemorrhage.

Authors:  Huang-Ping Yu; Irshad H Chaudry
Journal:  Shock       Date:  2009-03       Impact factor: 3.454

10.  Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation.

Authors:  N R Mudalagiri; M M Mocanu; C Di Salvo; S Kolvekar; M Hayward; J Yap; B Keogh; D M Yellon
Journal:  Br J Pharmacol       Date:  2007-10-22       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.